FR2760972B1 - Utilisation de l-citrulline en medecine orthomoleculaire pour la vasoprotection, le tonus relaxatif des muscles lisses et la protection cellulaires - Google Patents

Utilisation de l-citrulline en medecine orthomoleculaire pour la vasoprotection, le tonus relaxatif des muscles lisses et la protection cellulaires

Info

Publication number
FR2760972B1
FR2760972B1 FR9802433A FR9802433A FR2760972B1 FR 2760972 B1 FR2760972 B1 FR 2760972B1 FR 9802433 A FR9802433 A FR 9802433A FR 9802433 A FR9802433 A FR 9802433A FR 2760972 B1 FR2760972 B1 FR 2760972B1
Authority
FR
France
Prior art keywords
vasoprotection
relaxative
tonus
citrulline
smooth muscles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9802433A
Other languages
English (en)
Other versions
FR2760972A1 (fr
Inventor
William H Waugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27123037&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2760972(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/807,757 external-priority patent/US6028107A/en
Application filed by Individual filed Critical Individual
Publication of FR2760972A1 publication Critical patent/FR2760972A1/fr
Application granted granted Critical
Publication of FR2760972B1 publication Critical patent/FR2760972B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR9802433A 1997-02-27 1998-02-27 Utilisation de l-citrulline en medecine orthomoleculaire pour la vasoprotection, le tonus relaxatif des muscles lisses et la protection cellulaires Expired - Fee Related FR2760972B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/807,757 US6028107A (en) 1997-02-27 1997-02-27 Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US08/961,639 US5874471A (en) 1997-02-27 1997-10-30 Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection

Publications (2)

Publication Number Publication Date
FR2760972A1 FR2760972A1 (fr) 1998-09-25
FR2760972B1 true FR2760972B1 (fr) 2003-01-10

Family

ID=27123037

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9802433A Expired - Fee Related FR2760972B1 (fr) 1997-02-27 1998-02-27 Utilisation de l-citrulline en medecine orthomoleculaire pour la vasoprotection, le tonus relaxatif des muscles lisses et la protection cellulaires

Country Status (5)

Country Link
US (1) US5874471A (fr)
AP (1) AP841A (fr)
CA (1) CA2229746C (fr)
FR (1) FR2760972B1 (fr)
GB (1) GB2322551B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
JP3843298B2 (ja) * 2001-02-05 2006-11-08 国立大学法人 奈良先端科学技術大学院大学 シトルリンを含有する活性酸素消去剤
JP2004518712A (ja) 2001-02-14 2004-06-24 ラート・マティアス 細胞の生体エネルギー代謝に関与する生化学的化合物の組成物及びそれの使用法
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
EP1564220A4 (fr) * 2002-11-21 2010-03-17 Chugai Pharmaceutical Co Ltd Excipient pour medicament a liberation retardee
WO2006002096A2 (fr) * 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Faibles doses de l-citrulline pour traiter des maladies
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
EP2679223A1 (fr) * 2006-04-04 2014-01-01 Nestec S.A. Traitements utilisant de la citrulline
CN101415414B (zh) * 2006-04-04 2013-06-12 雀巢产品技术援助有限公司 瓜氨酸在制备治疗矫正脓毒症患者中精氨酸缺乏的药物中的用途
CA2709660C (fr) 2008-01-04 2018-06-05 Nestec S.A. Compositions comprenant des acides gras insatures et des composes liberant de l'oxyde nitrique et leur utilisation pour ameliorer des fonctions cognitives et apparentees
KR101932831B1 (ko) 2008-01-31 2018-12-27 반더빌트유니버시티 관상과 동맥의 동맥류성 지주막하출혈의 치료를 위한 조성물 및 방법
PT2247297T (pt) * 2008-01-31 2019-04-24 Univ Vanderbilt Tratamento terapêutico para estados pulmonares
FR2937550B1 (fr) * 2008-10-29 2010-12-10 Univ Paris Descartes Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion
FR2943901B1 (fr) 2009-04-01 2017-11-17 E(Ye)Brain Procede et systeme de detection d'anomalies oculomotrices.
WO2012027277A2 (fr) * 2010-08-21 2012-03-01 Hydropep, Llc Compositions permettant de réduire les effets délétères du stress et du vieillissement
JP5748441B2 (ja) * 2010-09-27 2015-07-15 株式会社明治 シトルリンを有効成分として含有する骨量低下改善剤
FR2970414B1 (fr) * 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
AT511776B1 (de) * 2011-07-26 2014-03-15 Gonadosan Gmbh Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität
EP2805730A1 (fr) * 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Donneurs d'oxyde nitrique pour le traitement du syndrome de fatigue chronique
AR111082A1 (es) * 2017-02-27 2019-05-29 Univ Vanderbilt Citrulina para el tratamiento de la crisis de células falciformes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411757A (en) * 1989-11-09 1995-05-02 Buist; Neil R. M. Palatable balanced amino acid-modified diet
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
GB2281207A (en) * 1993-08-28 1995-03-01 Univ Sheffield Treatment of laminitis with l-arginine
DE4341000A1 (de) * 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
DE19533330A1 (de) * 1995-09-11 1997-03-13 Beiersdorf Ag Gegen Hautkrebs wirksame topische Zubereitungen

Also Published As

Publication number Publication date
CA2229746C (fr) 2002-05-07
AP841A (en) 2000-06-02
GB2322551A (en) 1998-09-02
CA2229746A1 (fr) 1998-08-27
GB9804025D0 (en) 1998-04-22
AP9801208A0 (en) 1998-03-31
FR2760972A1 (fr) 1998-09-25
GB2322551B (en) 1999-09-01
US5874471A (en) 1999-02-23

Similar Documents

Publication Publication Date Title
FR2760972B1 (fr) Utilisation de l-citrulline en medecine orthomoleculaire pour la vasoprotection, le tonus relaxatif des muscles lisses et la protection cellulaires
ATE389019T1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
HUP0300602A3 (en) Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use
DE68905374D1 (de) Mittel zur vorbeugung und abhilfe gegen ischaemische verletzungen.
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
ATE285767T1 (de) Kombinationstherapie, enthaltend atorvastatin und bluddrucksenkendes mittel
NO995135D0 (no) Fremstilling av höyaktive katalysatorer, katalysatorene og deres anvendelse
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
DK1181027T3 (da) Diætetisk eller farmaceutisk præparat til anvendelse til forebyggelsen eller behandling af hyperoxaluri
ITMI982280A0 (it) Alcune n-(2-april-propionil)-solfonammidi e preparazioni farmaceutiche che le contengono
DE69917477D1 (de) Vorrichtung zur arzneistoffabgabe, insbesondere zur verabreichung von progestinen und östrogenen
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
MX9101787A (es) Formulaciones,metodos y dispositivos anticonceptivos transdermicos
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HK1001286A1 (en) Benzopyrans and their use as therapeutic agents.
FR2809883B1 (fr) Duplexeur et dispositif de communication mobile qui l'utilise
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
DE69905519D1 (de) Blockcopolymer und Zusammensetzung enthaltend das Blockcopolymer

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20111102